Interleukin-10-819C>T polymorphism contributed to cancer risk: Evidence from 29 studies

Cytokine

Volumn 61, Issue 1, 2013, Pages 139-145

  Ding, Qi ^a   Fan, Bo ^a   Fan, ZhiJiang ^a   Ding, Li ^a   Li, Feng ^a   Tu, Wenjian ^a   Jin, Xiaohua ^a   Shi, Ying ^a   Wang, Jing ^a  

^a Affiliated Changshu Hospital of Suzhou University   (China)

Author keywords

Cancer; Interleukin 10; Meta analysis; Polymorphism

Indexed keywords

INTERLEUKIN 10; MESSENGER RNA;

AFRICAN AMERICAN; ARTICLE; ASIAN; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNICITY; EUROPEAN AMERICAN; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; STOMACH CANCER;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; LINKAGE DISEQUILIBRIUM; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK; SMOKING;

EID: 84869879621     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.09.008     Document Type: Article

References (67)

1. Mocellin S., Marincola F.M., Young H.A. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005, 78:1043-1051.
2. Huang S., Xie K., Bucana C.D., Ullrich S.E., Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996, 2:1969-1979.
3. Stearns M.E., Rhim J., Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999, 5:189-196.
4. Kozlowski L., Zakrzewska I., Tokajuk P., Wojtukiewicz M.Z. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003, 48:82-84.
5. Budiani D.R., Hutahaean S., Haryana S.M., Soesatyo M.H., Sosroseno W. Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Microbiol Immunol Infect 2002, 35:265-268.
6. Jebreel A., Mistry D., Loke D., Dunn G., Hough V., Oliver K., et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007, 121:246-252.
7. Uwatoko N., Tokunaga T., Hatanaka H., Osada H., Kawakami T., Yamazaki H., et al. Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma. Int J Oncol 2002, 20:729-733.
8. Neuner A., Schindel M., Wildenberg U., Muley T., Lahm H., Fischer J.R. Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 2002, 101:287-292.
9. Lech-Maranda E., Bienvenu J., Michallet A.S., Houot R., Robak T., Coiffier B., et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 2006, 17:60-66.
10. De Vita F., Orditura M., Galizia G., Romano C., Roscigno A., Lieto E., et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000, 117:365-373.
11. Kingo K., Ratsep R., Koks S., Karelson M., Silm H., Vasar E. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci 2005, 37:111-113.
12. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
13. Zabaleta J., Lin H.Y., Sierra R.A., Hall M.C., Clark P.E., Sartor O.A., et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008, 29:573-578.
14. Oh S.S., Chang S.C., Cai L., Cordon-Cardo C., Ding B.G., Greenland S., et al. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer 2010, 127:2169-2182.
15. Andrie E., Michos A., Kalampoki V., Pourtsidis A., Moschovi M., Polychronopoulou S., et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol 2009, 83:334-342.
16. Cozar J.M., Romero J.M., Aptsiauri N., Vazquez F., Vilchez J.R., Tallada M., et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007, 68:698-704.
17. Guzowski D., Chandrasekaran A., Gawel C., Palma J., Koenig J., Wang X.P., et al. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech 2005, 16:154-166.
18. Savage S.A., Abnet C.C., Haque K., Mark S.D., Qiao Y.L., Dong Z.W., et al. Polymorphisms in interleukin-2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk chinese population. Cancer Epidemiol Biomarkers Prev 2004, 13:1547-1549.
19. Nieters A., Yuan J.M., Sun C.L., Zhang Z.Q., Stoehlmacher J., Govindarajan S., et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005, 103:740-748.
20. Li Y., Chang S.C., Goldstein B.Y., Scheider W.L., Cai L., You N.C., et al. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol 2011, 35:362-368.
21. Lech-Maranda E., Baseggio L., Charlot C., Rigal D., Berger F., Jamroziak K., et al. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 2007, 48:2235-2238.
22. Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies, vol. II. IARC Sci Publ; 1987. p. 1--406.
23. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses Bmj 2003, 327:557-560.
24. Midgette A.S., Wong J.B., Beshansky J.R., Porath A., Fleming C., Pauker S.G. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994, 14:108-117.
25. Whitehead A., Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991, 10:1665-1677.
26. Thakkinstian A., McElduff P., D'Este C., Duffy D., Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005, 24:1291-1306.
27. Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Konsgen D, Sun P, et al. Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. Gynecol Oncol. 2007;104:680-5.
28. Cacev T., Radosevic S., Krizanac S., Kapitanovic S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008, 29:1572-1580.
29. Faupel-Badger J.M., Kidd L.C., Albanes D., Virtamo J., Woodson K., Tangrea J.A. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008, 19:119-124.
30. Gunter M.J., Canzian F., Landi S., Chanock S.J., Sinha R., Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006, 15:1126-1131.
31. Howell W.M., Turner S.J., Bateman A.C., Theaker J.M. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001, 2:25-31.
32. Kesarwani P., Ahirwar D.K., Mandhani A., Singh A.N., Dalela D., Srivastava A.N., et al. IL-10-1082G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009, 27:389-396.
33. Lan Q., Zheng T., Rothman N., Zhang Y., Wang S.S., Shen M., et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006, 107:4101-4108.
34. Liu J., Song B., Bai X., Liu W., Li Z., Wang J., et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010, 10:456.
35. Liu J., Song B., Wang J.L., Li Z.J., Li W.H., Wang Z.H. Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol 2011, 17:1362-1367.
36. Lech-Maranda E., Baseggio L., Bienvenu J., Charlot C., Berger F., Rigal D., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004, 103:3529-3534.
37. Michaud D.S., Daugherty S.E., Berndt S.I., Platz E.A., Yeager M., Crawford E.D., et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006, 66:4525-4530.
38. Purdue M.P., Lan Q., Kricker A., Grulich A.E., Vajdic C.M., Turner J., et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis 2007, 28:704-712.
39. Purdue M.P., Sakoda L.C., Graubard B.I., Welch R., Chanock S.J., Sesterhenn I.A., et al. A case-control investigation of immune function gene polymorphisms and risk of testicular germ cell tumors. Cancer Epidemiol Biomarkers Prev 2007, 16:77-83.
40. Roh J.W., Kim M.H., Seo S.S., Kim S.H., Kim J.W., Park N.H., et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 2002, 184:57-63.
41. Seifart C., Plagens A., Dempfle A., Clostermann U., Vogelmeier C., von Wichert P., et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 2005, 21:157-165.
42. Shih C.M., Lee Y.L., Chiou H.L., Hsu W.F., Chen W.E., Chou M.C., et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung cancer 2005, 50:291-297.
43. Sugimoto M., Furuta T., Shirai N., Nakamura A., Kajimura M., Sugimura H., et al. Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J Gastroenterol Hepatol 2007, 22:1443-1449.
44. Wei Y.S., Kuang X.H., Zhu Y.H., Liang W.B., Yang Z.H., Tai S.H., et al. Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens 2007, 70:12-17.
45. Wu M.S., Wu C.Y., Chen C.J., Lin M.T., Shun C.T., Lin J.T. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer. 2003, 104:617-623.
46. Yao J.G., Gao L.B., Liu Y.G., Li J., Pang G.F. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 2008, 388:84-88.
47. Zambon C.F., Basso D., Navaglia F., Belluco C., Falda A., Fogar P., et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 2005, 29:141-152.
48. Zeng X, Li Y, Liu T, Zhang J. Diverse H. pylori strains, IL-10 promoter polymorphisms with high morbidity of gastric cancer in Hexi area of Gansu Province, China. Mol Cell Biochem. 2011;362:241-8.
49. He J.R., Chen L.J., Su Y., Cen Y.L., Tang L.Y., Yu D.D., et al. Joint effects of Epstein-Barr virus and polymorphisms in interleukin-10 and interferon-gamma on breast cancer risk. J Infect Dis 2012, 205:64-71.
50. Westendorp R.G., Langermans J.A., Huizinga T.W., Elouali A.H., Verweij C.L., Boomsma D.I., et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997, 349:170-173.
51. Bienvenu J., Doche C., Gutowski M.C., Lenoble M., Lepape A., Perdrix J.P. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995, 25(Suppl. 2):S80-4.
52. Lim S., Crawley E., Woo P., Barnes P.J. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998, 352:113.
53. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
54. Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I., Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999, 42:1101-1108.
55. Lazarus M., Hajeer A.H., Turner D., Sinnott P., Worthington J., Ollier W.E., et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997, 24:2314-2317.
56. Kube D., Platzer C., von Knethen A., Straub H., Bohlen H., Hafner M., et al. Isolation of the human interleukin 10 promoter. characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995, 7:1-7.
57. Clerici M., Merola M., Ferrario E., Trabattoni D., Villa M.L., Stefanon B., et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997, 89:245-250.
58. Merendino R.A., Arena A., Capozza A.B., Chillemi S., Mesiti M. Serum levels of interleukin-10 in patients affected by breast cancer. Immunol Lett 1996, 53:59-60.
59. Sun T., Miao X., Zhang X., Tan W., Xiong P., Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004, 96:1030-1036.
60. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000, 92:1764-1772.
61. Blot W.J., McLaughlin J.K., Winn D.M., Austin D.F., Greenberg R.S., Preston-Martin S., et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988, 48:3282-3287.
62. Setiawan V.W., Stram D.O., Nomura A.M., Kolonel L.N., Henderson B.E. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007, 166:932-940.
63. Vassallo R., Tamada K., Lau J.S., Kroening P.R., Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 2005, 175:2684-2691.
64. Salazar-Onfray F., Petersson M., Franksson L., Matsuda M., Blankenstein T., Karre K., et al. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 1995, 154:6291-6298.
65. Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994, 180:2371-2376.
66. Chen Y.M., Yang W.K., Whang-Peng J., Tsai C.M., Perng R.P. An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. Lung cancer 2001, 31:25-30.
67. Hagenbaugh A., Sharma S., Dubinett S.M., Wei S.H., Aranda R., Cheroutre H., et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997, 185:2101-2110.